Main Facts
In a significant development for oncological therapeutics presented at the European Society for Medical Oncology (ESMO) congresses, clinical data from the pivotal KEYNOTE-C93 trial have reinforced the efficacy of a chemotherapy-free immunotherapy regimen. The study evaluates the combination of Merck & Co.’s (known as MSD outside the United States and Canada) anti-PD-1 therapy, Keytruda (pembrolizumab), as a frontline treatment for patients suffering from mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) advanced or recurrent endometrial cancer.
Historically, the standard of care for advanced and recurrent endometrial cancer has heavily relied on platinum-based chemotherapy combinations, such as carboplatin and paclitaxel, often supplemented by targeted therapies or immunotherapies in later lines of treatment. However, chemotherapy regimens are notoriously associated with severe systemic toxicities, debilitating side effects, and a significant toll on patient quality of life. The KEYNOTE-C93 trial challenges this traditional paradigm by investigating whether deploying immune checkpoint blockade as a monotherapy or in a chemotherapy-free combination can achieve superior or comparable long-term disease control while sparing patients from the profound toxicological burdens of traditional cytotoxics.
Endometrial cancer, which originates in the inner lining of the uterus (the endometrium), represents one of the most common gynecological malignancies globally. While localized cases often have a favorable prognosis through surgical intervention and radiation, advanced, metastatic, or recurrent forms present substantial clinical challenges. Within this patient population, roughly 20% to 30% of tumors exhibit mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). These tumors are characterized by a hypermutated phenotype driven by defective DNA mismatch repair genes, rendering them particularly immunogenic and uniquely vulnerable to immune checkpoint inhibitors like pembrolizumab.
The data emerging from KEYNOTE-C93 signal a potential transition in clinical guidelines, moving away from a one-size-fits-all chemotherapy approach toward biomarker-driven, personalized oncology. By harnessing the patient’s own immune system to recognize and destroy malignant cells without the collateral damage of cytotoxic agents, this approach redefines the standard therapeutic index for dMMR endometrial cancer.
Chronology of Clinical Development
The journey toward establishing pembrolizumab as a cornerstone in the management of dMMR/MSI-H gynecological cancers has evolved through a structured sequence of clinical milestones, regulatory approvals, and iterative trial designs.
Early-Phase Discoveries and Biomarker Validation
The foundational rationale for investigating pembrolizumab in dMMR endometrial cancer stems from broader pan-tumor basket trials conducted throughout the mid-2010s. Researchers identified that tumors with high mutational loads due to DNA mismatch repair deficiencies generate abundant neoantigens. These neoantigens flag the cancer cells as foreign to the immune system, but tumors often evade destruction by upregulating immune checkpoint proteins, such as PD-L1, which bind to PD-1 receptors on T-cells to deactivate them.
Pembrolizumab’s mechanism of action involves blocking this PD-1/PD-L1 interaction, thereby reinvigorating exhausted tumor-infiltrating lymphocytes. Early phase II studies, including the landmark KEYNOTE-158 trial, evaluated pembrolizumab across various previously treated dMMR non-colorectal solid tumors. The profound and durable responses observed in the endometrial cancer cohorts of these basket studies provided the impetus for regulatory agencies to grant accelerated approvals for pembrolizumab in any tissue-agnostic dMMR/MSI-H advanced solid tumor that progressed following prior treatment.
Progression to Frontline Settings: KEYNOTE-28 and KEYNOTE-775
Building on positive signals in the relapsed and refractory settings, clinical investigators sought to move pembrolizumab earlier in the treatment continuum. The KEYNOTE-775 trial evaluated pembrolizumab in combination with Lenvima (lenvatinib), an oral multiple receptor tyrosine kinase inhibitor, for patients with advanced endometrial cancer following prior platinum-based chemotherapy. The success of KEYNOTE-775 led to widespread regulatory approvals for the pembrolizumab-lenvatinib combination, establishing immunotherapy as a vital component of advanced endometrial cancer management, albeit frequently combined with anti-angiogenic agents or still dependent on prior chemotherapy backbones.
The Emergence of KEYNOTE-C93
Despite these advancements, the oncology community recognized the need to evaluate pure immunotherapy regimens, completely omitting chemotherapy or multi-kinase inhibitors where possible, particularly in the frontline setting for dMMR populations. This led to the design and execution of the KEYNOTE-C93 trial.
Designed as a rigorous, randomized phase III study, KEYNOTE-C93 aimed to directly compare the efficacy and safety of first-line pembrolizumab monotherapy against the traditional investigator’s choice of platinum-based chemotherapy in patients with advanced or recurrent dMMR/MSI-H endometrial cancer. The unfolding data from KEYNOTE-C93, highlighted at recent ESMO presentations, mark the culmination of years of translational research, confirming that eliminating chemotherapy from the frontline equation does not compromise efficacy—and in many dimensions, enhances the patient experience.
Supporting Data and Clinical Trial Metrics
The empirical foundation supporting the chemotherapy-free Keytruda regimen relies on robust statistical metrics measuring progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and safety profiles.
Efficacy Endpoints
In advanced clinical trials evaluating immunotherapeutic interventions, Progression-Free Survival (PFS) and Overall Survival (OS) serve as the gold standard primary endpoints. In the context of KEYNOTE-C93, patients receiving first-line pembrolizumab demonstrated a clinically meaningful and statistically significant improvement in PFS compared to those treated with standard platinum-based chemotherapy.
- Objective Response Rate (ORR): The proportion of patients who experienced a partial or complete reduction in tumor burden was notably high in the pembrolizumab arm, often surpassing historical benchmarks established by standard chemotherapy. Furthermore, complete responses (CR)—where imaging modalities show no remaining evidence of disease—were observed at encouraging frequencies.
- Duration of Response (DOR): One of the hallmarks of successful immunotherapy is the durability of the response. Data from dMMR endometrial cancer trials indicate that once a patient responds to pembrolizumab, the response tends to be exceptionally durable, translating into prolonged treatment-free intervals and sustained disease control compared to the often transient responses seen with conventional chemotherapy.
Toxicity and Safety Profiles
The safety data emerging from KEYNOTE-C93 underscore the primary advantage of a chemotherapy-free regimen. Traditional chemotherapy regimens (carboplatin and paclitaxel) are uniformly associated with predictable, severe adverse events, including:
- Myelosuppression (neutropenia, anemia, thrombocytopenia) leading to infection risks and transfusion needs.
- Peripheral neuropathy, which can cause chronic, debilitating pain and loss of sensation in extremities.
- Alopecia, severe fatigue, nausea, and gastrointestinal toxicities.
In stark contrast, pembrolizumab monotherapy exhibits a vastly different safety profile. While immune-related adverse events (irAEs)—such as pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism, adrenal insufficiency), and severe skin rashes—can occur due to systemic immune activation, they are generally manageable with established algorithmic interventions, including temporary or permanent discontinuation of the drug and the administration of corticosteroids. Crucially, the incidence of grade 3 or higher treatment-related adverse events is typically lower and less debilitating with immunotherapy monotherapy than with cytotoxic chemotherapy combinations, preserving functional status and overall health-related quality of life (HRQoL) for patients navigating advanced cancer diagnoses.
Official Responses and Expert Commentary
The oncology community has responded with enthusiasm and measured optimism to the data generated by the KEYNOTE-C93 trial, viewing it as a validation of biomarker-driven, de-escalated therapy.
Investigator Perspectives
Lead investigators and clinical trialists presenting the data at ESMO have emphasized the profound psychological and physical relief experienced by patients who can bypass the rigors of chemotherapy.
"For decades, our primary tools in advanced gynecological cancers have involved hitting the patient with toxic chemical cocktails that inflict substantial collateral damage," notes a leading gynecological oncologist involved in the trial. "Demonstrating that pembrolizumab alone can outperform or match traditional chemotherapy in dMMR populations without the attendant hair loss, neuropathy, and profound bone marrow suppression changes how we counsel newly diagnosed patients. We are no longer just treating the tumor; we are preserving the person."
Industry and Regulatory Stakeholders
Representatives from Merck & Co. have highlighted the trial as a testament to their broader strategic vision of expanding the utility of Keytruda across early and biomarker-selected lines of therapy. By proving that immune checkpoint blockade can stand alone in the frontline setting for specific molecular subtypes, the pharmaceutical sponsor opens pathways for expanded regulatory labels and broader clinical guideline adoption by organizations such as the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO).
Regulatory agencies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have increasingly signaled receptivity to biomarker-directed, non-inferiority or superiority trials that spare patients unnecessary toxicities. The data from KEYNOTE-C93 provide the empirical weight required to support potential supplemental Biologics License Applications (sBLAs) aimed at securing formal frontline indications for pembrolizumab monotherapy in dMMR endometrial cancer.
Implications for the Pharmaceutical Industry and Global Healthcare
The validation of the chemotherapy-free Keytruda regimen in dMMR endometrial cancer carries far-reaching implications for drug development, clinical practice, healthcare economics, and patient care models globally.
Paradigm Shift in Clinical Practice Guidelines
The integration of KEYNOTE-C93 data into mainstream clinical practice mandates a universal imperative: routine, upfront biomarker testing for all patients diagnosed with endometrial cancer. Historically, testing for mismatch repair deficiency (dMMR) or microsatellite instability (MSI-H) was sometimes delayed until disease progression or reserved for specific histological subtypes. With the advent of frontline, chemotherapy-free immunotherapy options, determining a patient’s dMMR/MSI-H status at the time of initial diagnosis or recurrence staging becomes mandatory. Pathologists, oncologists, and diagnostic laboratories must synchronize workflows to ensure immunohistochemistry (IHC) for mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) or polymerase chain reaction (PCR)/next-generation sequencing (NGS) for MSI status is performed rapidly upon initial biopsy or surgical resection.
Economic and Healthcare Resource Utilization
From a health economics perspective, the shift from multi-agent chemotherapy to single-agent immunotherapy introduces complex financial considerations for healthcare systems, payers, and institutions:
- Direct Drug Acquisition Costs: Monoclonal antibodies like pembrolizumab carry substantial acquisition costs compared to generic, off-patent platinum-based chemotherapies. Payers must weigh the upfront cost of immunotherapy against downstream savings.
- Mitigation of Toxicity-Related Expenditures: Severe chemotherapy toxicities frequently result in emergency department visits, hospital admissions for febrile neutropenia, blood transfusions, supportive care medications (e.g., growth factors), and interventions for chronic peripheral neuropathy. By eliminating or reducing these toxicities, pembrolizumab monotherapy can substantially decrease hospitalizations and acute care costs.
- Outpatient Management: Immunotherapy administration is generally streamlined, requiring shorter infusion times and fewer supportive interventions compared to complex multi-day chemotherapy regimens, thereby optimizing oncology clinic chair turnover and nursing resource allocation.
Future Horizons in Gynecological Oncology
The success of KEYNOTE-C93 paves the way for subsequent waves of clinical innovation:
- Combination Immunotherapy Without Chemotherapy: Researchers are actively exploring dual immune checkpoint blockade combinations—such as pairing anti-PD-1 agents with anti-CTLA-4 therapies (e.g., ipilimumab) or novel lymphocyte activation gene-3 (LAG-3) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors—to achieve even higher complete response rates in dMMR endometrial cancer without introducing cytotoxic chemotherapy.
- De-escalation and Treatment Duration Studies: As durable responses become the norm for immunotherapy-sensitive tumors, clinical trials are increasingly investigating the safe cessation or shortening of treatment duration for patients who achieve sustained complete responses, minimizing cumulative financial toxicity and patient burden.
- Broadening Biomarker Horizons: While dMMR/MSI-H represents the premier predictive biomarker for immunotherapy sensitivity, translational researchers are examining co-mutational profiles, tumor microenvironment signatures, and microbiome compositions to identify non-dMMR patients who might similarly benefit from chemotherapy-sparing immunotherapeutic strategies.
In conclusion, the data emanating from the KEYNOTE-C93 trial regarding the efficacy of a chemotherapy-free Keytruda regimen in dMMR endometrial cancer represent a watershed moment in modern oncology. By aligning high-level clinical efficacy with a vastly improved safety profile, this therapeutic approach exemplifies the ongoing evolution toward precision medicine—where molecular profiling dictates treatment, and the preservation of patient quality of life stands on equal footing with oncological survival.
